Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.
about
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory DiseasesRheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters FunctionDisparity in disaster preparedness among rheumatoid arthritis patients with various general health, functional, and disability conditions.Impact of natural disasters on the functional and health status of patients with rheumatoid arthritis.Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis.Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective.Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS andWindow of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.Coping with prescription medication costs: a cross-sectional look at strategies used and associations with the physical and psychosocial health of individuals with arthritis.Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid ArthritisAdherence to Methotrexate therapy in Rheumatoid Arthritis.Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis.A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases.Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy.Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?Autonomous online health assessment questionnaire registry in daily clinical practice.Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis.Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound.The added value of musculoskeletal ultrasound to clinical evaluation in the treatment decision of rheumatoid arthritis outpatients: physician experience matters.Adherence to systemic therapies for immune-mediated inflammatory diseases in Lebanon: a physicians' survey from three medical specialties.What constitutes uncertainty in systemic lupus erythematosus and rheumatoid arthritis?Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.Compliance with treatment of rheumatoid arthritis.Effect of long-term low dose prednisolone administration on bone mineral density: Relating to non-compliant women with rheumatoid arthritis.
P2860
Q26778585-564E3000-9C07-4FC7-B392-9A32E8627A0EQ28552801-0E045CD2-7AC2-47C8-9F67-4C28AE4DA004Q30224838-2FAB2173-54E9-4262-A2A9-6C694E48F05DQ30226760-76EFBCD4-161A-474E-BABE-D8FFB07DE0B4Q33629614-B2D56C5A-5282-4B0C-8DB2-47E1749F0F49Q34267352-91F2D3FC-7F14-4266-B556-C153B048C748Q34449612-9938AE58-CABA-447A-ABEC-91BB142EC97EQ35185494-03B6D460-38B0-425F-9681-0A19DF1F2A56Q35842618-8CAA3391-2E04-4CAA-B9A9-91000371047DQ36064093-11A418E5-2065-4E5D-8EF4-FC2471B2E70CQ36236489-137EBF5C-3FA0-4B7B-88B8-2A4F4872DB27Q36480601-F109C2A0-E114-4A37-A9E7-B35EB1EA1160Q36876445-232621FA-B078-4C74-BB5E-2329C72FA2C3Q38654773-88A6C08A-63FB-4C36-8B23-312511186B60Q38662236-CB6B1DFF-57A8-4779-923B-8909F69EF2BBQ38960132-1E2AD7CE-C2AC-4B41-8483-CF2DFBA3B165Q38963734-400E3243-5C6D-4753-A82A-7824A24A2F34Q39489304-A9150FCA-F3E7-43A5-BB46-F966C8DBF489Q39672399-6004311D-5321-42AC-BC70-56AD61665A8FQ40550160-92B2D598-35D2-43FD-86D8-0E117944CF54Q41282388-361A1783-2150-426E-9D3E-1308B970754FQ41816131-06C4673A-1DD6-4BB0-948A-0DC155F044C5Q47405669-DCA2F0A4-8357-4D10-B661-FF25FA3B4A0BQ48282881-4D829E1F-902D-4636-B8D3-86F0F483ECD8Q48372838-2F319F14-1216-44D9-A28C-C36B69830354Q50608134-716489E6-4AE3-43DF-8DBE-46858AEFE1BEQ55092131-201EDE85-D163-4D35-944D-4DBBDA6024FE
P2860
Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Medication persistence over 2 ...... activity and with disability.
@en
Medication persistence over 2 ...... activity and with disability.
@nl
type
label
Medication persistence over 2 ...... activity and with disability.
@en
Medication persistence over 2 ...... activity and with disability.
@nl
prefLabel
Medication persistence over 2 ...... activity and with disability.
@en
Medication persistence over 2 ...... activity and with disability.
@nl
P2093
P2860
P356
P1476
Medication persistence over 2 ...... activity and with disability.
@en
P2093
Antonio R Villa
Irazú Contreras-Yáñez
Javier Cabiedes
Marina Rull-Gabayet
Virginia Pascual-Ramos
P2860
P2888
P356
10.1186/AR2620
P577
2009-02-19T00:00:00Z
P5875
P6179
1049370456